|Articles|July 1, 2004
Macugen approval process moves forward
Eyetech Pharmaceuticals Inc. and Pfizer Inc. have filed a new drug application with the FDA for the 0.3 mg dose of pegaptanib sodium injection (Macugen) as a treatment for AMD (also see Page 46 in this issue).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
2
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment
3
Novel therapy for incision-free keratoconus: Q&A with Gloria B. Chiu, OD, FAAO, FSLS
4
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study
5













































.png)


